22エピソード

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • 科学

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Jay B. Wish, MD - Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

    Jay B. Wish, MD - Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

    Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

    • 1 時間12分
    • video
    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Go online to PeerView.com/YNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView onDemand activity, based on an educational session from the 2019 Scientific Sessions of the American Heart Association in Philadelphia, Pennsylvania, features a panel of cardiology, endocrinology, and primary care experts, who provide their clinical perspectives on assessing patients with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular (CV) disease and other risk factors. These experts discuss recent and emerging data for antihyperglycemic agents (ie, GLP-1 receptor agonists and SGLT2 inhibitors) and how to incorporate this practice-changing information into individualized treatment plans for these high-risk patients. Upon completion of this activity, participants should be better able to: Screen patients with or at high risk of CV disease for T2DM, Assess individual patients with T2DM for risk factors that frequently complicate diabetes management (ie, history of atherosclerotic CV disease, heart failure, chronic kidney disease, hypoglycemia, obesity), Design individualized treatment regimens that consider and incorporate recent and emerging data for antihyperglycemic agents that have been shown to reduce CV risk in patients with T2DM, Collaborate with multidisciplinary colleagues to successfully reduce CV risk in individual patients with T2DM

    • 1 時間18分
    • video
    Matthew R. Weir, MD - Addressing the Disease Burden Associated With Anemia of Chronic Kidney Disease: Expert Insight on the Clinical Potential of HIF-PH Inhibitors

    Matthew R. Weir, MD - Addressing the Disease Burden Associated With Anemia of Chronic Kidney Disease: Expert Insight on the Clinical Potential of HIF-PH Inhibitors

    Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

    • 41分
    • video
    Javed Butler, MD, MPH, MBA - Early Recognition and Management of Chronic Heart Failure in the Primary Care Setting

    Javed Butler, MD, MPH, MBA - Early Recognition and Management of Chronic Heart Failure in the Primary Care Setting

    Go online to PeerView.com/RNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in heart failure discusses the early diagnosis and management of CHF. Upon completion of this activity, participants should be better able to: Implement evidence-based guidelines for early recognition and diagnosis of CHF, Apply available CHF therapies based on ACC/AHA/HFSA guidelines and clinical efficacy and safety data, Employ strategies to promote adherence to therapy and lifestyle modifications among patients with CHF

    • 42分
    • video
    Julia Batten, APRN, MSN, MPH - Virginia J. Seery, MSN, RN, ANP-BC - The Urologic Nurse Meets the Challenge of Renal Cell Carcinoma: Insights on Patient Care in an Expanding Treatment Landscape

    Julia Batten, APRN, MSN, MPH - Virginia J. Seery, MSN, RN, ANP-BC - The Urologic Nurse Meets the Challenge of Renal Cell Carcinoma: Insights on Patient Care in an Expanding Treatment Landscape

    Go online to PeerView.com/MDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView onDemand activity based on a nurse-led program at the SUNA 2019 uroLogic Conference, experts on modern RCC treatment (including immunotherapies and TKIs) offer valuable, practical insights on the current therapeutic and regulatory landscape in RCC, real-world application of evidence on novel targeted and immunotherapeutic regimens, the importance of counseling patients on therapeutic expectations with immune checkpoint inhibitors and TKIs, and the recognition and management of unique safety issues associated with newer agents in RCC. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety findings on novel regimens, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, for management of patients with renal cell carcinoma (RCC), Provide appropriate education and guidance to patients with RCC on available and emerging targeted- and immuno-therapeutic options in different disease settings, Counsel patients with RCC receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors on appropriate strategies to manage treatment-related complications

    • 49分
    • video
    James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

    James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

    Go online to PeerView.com/ASM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in primary care, endocrinology, and diabetes education offer insights on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Reconcile recommendations offered in evidence-based clinical guidelines focusing on individualized management of type 2 diabetes mellitus (T2DM), Identify and assess patient factors and health status to appropriately individualize glycemic targets and antihyperglycemic therapy in patients with T2DM, Acknowledge the preferred role and placement of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors in current T2DM treatment algorithms.

    • 1 時間12分

科学のトップPodcast

他のリスナーはこちらのサブスクリプションにも登録しています